このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

敗血症における免疫機能障害の評価

2026年9月21日 更新者:University of Minnesota

Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.

調査の概要

状態

募集

条件

研究の種類

観察的

入学 (推定)

150

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Mrunmayi Tilak
  • 電話番号:612-624-9990
  • メール:mtilak@umn.edu

研究場所

    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55455
        • 募集
        • University of Minnesota
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients with and without sepsis in the ICU, compared to healthy volunteers

説明

ICU With Sepsis Inclusion Criteria:

  • Age ≥ 18

  • Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"

  • Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:

    1. Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
    2. An alteration in mental status
    3. Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
    1. An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)

ICU Without Sepsis Inclusion Criteria:

  • Age ≥ 18
  • Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis

Healthy Volunteer Inclusion Criteria

  • Age greater or equal to 18
  • ASA status 1, 2 or 3
  • May include patients who are receiving dialysis in an outpatient setting

Exclusion Criteria (all groups):

  • Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
  • Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
  • Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
  • Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
  • Patients with active or a history of acute or chronic lymphocytic leukemia
  • Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
  • Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
  • Participation in another investigational interventional drug study within the past 4 weeks
  • Current pregnancy
  • Current incarceration

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_CONTROL
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
健康ボランティア

No intervention is included in this study

敗血症のICU患者

No intervention is included in this study

敗血症のないICU患者

No intervention is included in this study

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
EliSpot - Day 1
時間枠:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
EliSpot - Day 4
時間枠:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
EliSpot - Day 7
時間枠:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
EliSpot - Day 14
時間枠:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
EliSpot - Day 21
時間枠:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
EliSpot - Day 28
時間枠:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Ex Vivo TNF Production - Day 1
時間枠:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Ex Vivo TNF Production - Day 4
時間枠:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Ex Vivo TNF Production - Day 7
時間枠:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Ex Vivo TNF Production - Day 14
時間枠:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Ex Vivo TNF Production - Day 21
時間枠:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Ex Vivo TNF Production - Day 28
時間枠:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
時間枠:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
時間枠:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
時間枠:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
時間枠:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
時間枠:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
時間枠:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Cytokines in Serum - Day 1
時間枠:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Cytokines in Serum - Day 4
時間枠:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Cytokines in Serum - Day 7
時間枠:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Cytokines in Serum - Day 14
時間枠:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Cytokines in Serum - Day 21
時間枠:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Cytokines in Serum - Day 28
時間枠:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Chemokines in Serum - Day 1
時間枠:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Chemokines in Serum - Day 4
時間枠:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Chemokines in Serum - Day 7
時間枠:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Chemokines in Serum - Day 14
時間枠:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Chemokines in Serum - Day 21
時間枠:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Chemokines in Serum - Day 28
時間枠:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Transcriptional Profiling - Day 1
時間枠:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Transcriptional Profiling - Day 4
時間枠:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Transcriptional Profiling - Day 7
時間枠:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Transcriptional Profiling - Day 14
時間枠:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Transcriptional Profiling - Day 21
時間枠:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Transcriptional Profiling - Day 28
時間枠:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
CBC - Day 1
時間枠:Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
CBC - Day 4
時間枠:Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
CBC - Day 7
時間枠:Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
CBC - Day 14
時間枠:Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
CBC - Day 21
時間枠:Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
CBC - Day 28
時間枠:Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Thomas Griffith, PhD、University of Minnesota

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年3月1日

一次修了 (推定)

2028年11月1日

研究の完了 (推定)

2028年11月1日

試験登録日

最初に提出

2025年8月26日

QC基準を満たした最初の提出物

2025年8月26日

最初の投稿 (実際)

2025年9月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月23日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する